JPWO2020206320A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020206320A5 JPWO2020206320A5 JP2021558657A JP2021558657A JPWO2020206320A5 JP WO2020206320 A5 JPWO2020206320 A5 JP WO2020206320A5 JP 2021558657 A JP2021558657 A JP 2021558657A JP 2021558657 A JP2021558657 A JP 2021558657A JP WO2020206320 A5 JPWO2020206320 A5 JP WO2020206320A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- pharmaceutical composition
- acid sequence
- seq
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Description
ある特定の実施形態は、LSD(例えば、ハンター症候群)の処置を必要とする対象のLSDの処置に使用するための本明細書に記載される医薬組成物を提供する。
本発明の実施形態において、例えば以下の項目が提供される。
(項目1)
医薬組成物であって、
a.以下を含むタンパク質分子:
i.EU番号付けによる、380、384、386、387、388、389、390、413、415、416、及び421からなる群から選択される少なくとも9つのアミノ酸残基位置に置換を含む第1Fcポリペプチド、ならびに
ii.イズロン酸-2-スルファターゼ(IDS)酵素に連結される第2Fcポリペプチドであって、IDSアミノ酸配列が、配列番号:1と少なくとも90%の同一性を有する配列を含む前記第2Fcポリペプチド、
b.緩衝液、ならびに
c.塩
を含み、前記医薬組成物のpHが、約5.5~7.0である、前記医薬組成物。
(項目2)
前記緩衝液が、リン酸緩衝液、酢酸緩衝液、アルギニン緩衝液、及びヒスチジン緩衝液からなる群から選択される、項目1に記載の医薬組成物。
(項目3)
前記リン酸緩衝液が、リン酸ナトリウム緩衝液またはリン酸カリウム緩衝液である、項目2に記載の医薬組成物。
(項目4)
前記塩がナトリウム塩である、項目1~3のいずれか1項に記載の医薬組成物。
(項目5)
前記ナトリウム塩が、塩化ナトリウム、硫酸ナトリウム、及びリン酸ナトリウムからなる群から選択される、項目4に記載の医薬組成物。
(項目6)
前記医薬組成物が界面活性剤をさらに含む、項目1~5のいずれか1項に記載の医薬組成物。
(項目7)
前記医薬組成物が、糖を含む安定剤をさらに含む、項目1~6のいずれか1項に記載の医薬組成物。
(項目8)
前記IDSアミノ酸配列が、配列番号:1、2及び3からなる群から選択される配列を含む、項目1~7のいずれか1項に記載の医薬組成物。
(項目9)
前記第1Fcポリペプチドが、EU番号付けによる、アミノ酸残基384、386、387、388、389、413、415、416、及び421位に置換を含む、項目1~8のいずれか1項に記載の医薬組成物。
(項目10)
前記IDSアミノ酸配列が、前記第2FcポリペプチドのN末端に連結される、項目1~9のいずれか1項に記載の医薬組成物。
(項目11)
前記IDSアミノ酸配列に連結される前記第2Fcポリペプチドが、配列番号:4または5と少なくとも95%の同一性を有するアミノ酸配列を含む、項目1~10のいずれか1項に記載の医薬組成物。
(項目12)
前記IDSアミノ酸配列に連結される前記第2Fcポリペプチドが、配列番号:4または5のアミノ酸配列を含む、項目1~10のいずれか1項に記載の医薬組成物。
(項目13)
前記第1Fcポリペプチドが、配列番号:6と少なくとも90%の同一性を有する配列を含む、項目1~12のいずれか1項に記載の医薬組成物。
(項目14)
前記第1Fcポリペプチドが、配列番号:6と少なくとも95%の同一性を有する配列を含む、項目1~12のいずれか1項に記載の医薬組成物。
(項目15)
前記第1Fcポリペプチドが、
a.380位にTrp、Leu、またはGlu、
b.384位にTyr、
c.386位にThr、
d.387位にGlu、
e.388位にTrp、
f.389位にSerまたはAla、
g.390位にSerまたはAsn、
h.413位にThr、
i.415位にGlu、
j.416位にGlu、及び
k.421位にPhe
を含む、項目1~14のいずれか1項に記載の医薬組成物。
(項目16)
前記第1Fcポリペプチドが、配列番号:6、7、25及び30のうちいずれか1つと少なくとも95%の配列同一性を有するアミノ酸配列を含み、前記IDSアミノ酸配列に連結される前記第2Fcポリペプチドが、配列番号:4または5と少なくとも95%の配列同一性を有するアミノ酸配列を含む、項目1~15のいずれか1項に記載の医薬組成物。
(項目17)
前記第1Fcポリペプチドが、配列番号:6のアミノ酸配列を含み、前記IDSアミノ酸配列に連結される前記第2Fcポリペプチドが、配列番号:4または5の配列を含む、項目16に記載の医薬組成物。
(項目18)
前記第1Fcポリペプチドが、配列番号:7のアミノ酸配列を含み、前記IDSアミノ酸配列に連結される前記第2Fcポリペプチドが、配列番号:4または5の配列を含む、項目16に記載の医薬組成物。
(項目19)
前記第1Fcポリペプチドが、配列番号:25のアミノ酸配列を含み、前記IDSアミノ酸配列に連結される前記第2Fcポリペプチドが、配列番号:4または5の配列を含む、項目16に記載の医薬組成物。
(項目20)
前記第1Fcポリペプチドが、配列番号:30のアミノ酸配列を含み、前記IDSアミノ酸配列に連結される前記第2Fcポリペプチドが、配列番号:4または5の配列を含む、項目16に記載の医薬組成物。
(項目21)
前記第1Fcポリペプチドが、配列番号:41、42、44及び49のうちいずれか1つと少なくとも95%の配列同一性を有するアミノ酸配列を含み、前記IDSアミノ酸配列に連結される前記第2Fcポリペプチドが、配列番号:39または40と少なくとも95%の配列同一性を有するアミノ酸配列を含む、項目1~15のいずれか1項に記載の医薬組成物。
(項目22)
前記第1Fcポリペプチドが、配列番号:41のアミノ酸配列を含み、前記IDSアミノ酸配列に連結される前記第2Fcポリペプチドが、配列番号:39または40の配列を含む、項目21に記載の医薬組成物。
(項目23)
前記第1Fcポリペプチドが、配列番号:42のアミノ酸配列を含み、前記IDSアミノ酸配列に連結される前記第2Fcポリペプチドが、配列番号:39または40の配列を含む、項目21に記載の医薬組成物。
(項目24)
前記第1Fcポリペプチドが、配列番号:44のアミノ酸配列を含み、前記IDSアミノ酸配列に連結される前記第2Fcポリペプチドが、配列番号:39または40の配列を含む、項目21に記載の医薬組成物。
(項目25)
前記第1Fcポリペプチドが、配列番号:49のアミノ酸配列を含み、前記IDSアミノ酸配列に連結される前記第2Fcポリペプチドが、配列番号:39または40の配列を含む、項目21に記載の医薬組成物。
(項目26)
前記タンパク質分子の濃度が約5~50mg/mLである、項目1~25のいずれか1項に記載の医薬組成物。
(項目27)
前記タンパク質分子の濃度が約10~30mg/mLである、項目1~26のいずれか1項に記載の医薬組成物。
(項目28)
前記タンパク質分子の濃度が約10mg/mLである、項目1~27のいずれか1項に記載の医薬組成物。
(項目29)
前記タンパク質分子の濃度が約20mg/mLである、項目1~27のいずれか1項に記載の医薬組成物。
(項目30)
前記タンパク質分子の濃度が約30mg/mLである、項目1~27のいずれか1項に記載の医薬組成物。
(項目31)
前記緩衝液の濃度が約5~50mMである、項目1~30のいずれか1項に記載の医薬組成物。
(項目32)
前記緩衝液の濃度が約10~30mMである、項目1~31のいずれか1項に記載の医薬組成物。
(項目33)
前記緩衝液の濃度が約20mMである、項目1~32のいずれか1項に記載の医薬組成物。
(項目34)
前記塩の濃度が約30~150mMである、項目1~33のいずれか1項に記載の医薬組成物。
(項目35)
前記塩の濃度が約50~137mMである、項目1~34のいずれか1項に記載の医薬組成物。
(項目36)
前記塩の濃度が約50mMである、項目1~35のいずれか1項に記載の医薬組成物。
(項目37)
前記塩の濃度が約137mMである、項目1~35のいずれか1項に記載の医薬組成物。
(項目38)
前記界面活性剤の濃度が約0.1~1.0mg/mLである、項目6~37のいずれか1項に記載の医薬組成物。
(項目39)
前記界面活性剤の濃度が約0.2~0.6mg/mLである、項目6~38のいずれか1項に記載の医薬組成物。
(項目40)
前記界面活性剤の濃度が約0.4mg/mLである、項目6~39のいずれか1項に記載の医薬組成物。
(項目41)
前記界面活性剤の濃度が約0.6mg/mLである、項目6~39のいずれか1項に記載の医薬組成物。
(項目42)
前記界面活性剤がポリソルベートを含む、項目6~41のいずれか1項に記載の医薬組成物。
(項目43)
前記界面活性剤が、ポリソルベート-20(PS-20)及びポリソルベート-80(PS-80)からなる群から選択される、項目42に記載の医薬組成物。
(項目44)
前記界面活性剤がポリソルベート-20(PS-20)である、項目43に記載の医薬組成物。
(項目45)
前記界面活性剤がポリソルベート-80(PS-80)である、項目43に記載の医薬組成物。
(項目46)
前記安定剤が、スクロースまたはトレハロースから選択される糖を含む、項目7~45のいずれか1項に記載の医薬組成物。
(項目47)
前記糖の濃度が約100~250mMである、項目7~46のいずれか1項に記載の医薬組成物。
(項目48)
前記糖の濃度が約175mMである、項目7~47のいずれか1項に記載の医薬組成物。
(項目49)
前記安定剤がスクロースを含む、項目7~48のいずれか1項に記載の医薬組成物。
(項目50)
前記組成物がメチオニンをさらに含む、項目1~49のいずれか1項に記載の医薬組成物。
(項目51)
前記メチオニンの濃度が約5~20mMである、項目50に記載の医薬組成物。
(項目52)
前記メチオニンの濃度が約10mMである、項目50または51のいずれか1項に記載の医薬組成物。
(項目53)
前記医薬組成物の前記pHが約5.5~6.5である、項目1~52のいずれか1項に記載の医薬組成物。
(項目54)
前記医薬組成物の前記pHが約6.5±0.5である、項目1~52のいずれか1項に記載の医薬組成物。
(項目55)
前記タンパク質分子が、約5.5~7.0のpHでインタクトなままである、項目1~54のいずれか1項に記載の医薬組成物。
(項目56)
前記医薬組成物が、液体組成物として提供される、項目1~55のいずれか1項に記載の医薬組成物。
(項目57)
前記医薬組成物が、凍結乾燥組成物として提供される、項目1~55のいずれか1項に記載の医薬組成物。
(項目58)
ハンター症候群の処置を必要とする対象のハンター症候群の処置方法であって、項目1~57のいずれか1項に記載の医薬組成物を提供し、それを前記対象に投与することを含む、前記方法。
(項目59)
前記医薬組成物が静脈内投与される、項目58に記載の方法。
(項目60)
ハンター症候群の処置を必要とする対象のハンター症候群の処置に使用するための、項目1~57のいずれか1項に記載の医薬組成物。
(項目61)
ハンター症候群の処置を必要とする対象のハンター症候群を処置するための医薬の調製における、項目1~57のいずれか1項に記載されるような医薬組成物の使用。
Certain embodiments provide pharmaceutical compositions described herein for use in treating LSD in a subject in need thereof (eg, Hunter Syndrome).
In embodiments of the present invention, for example, the following items are provided.
(Item 1)
A pharmaceutical composition comprising
a. Protein molecules containing:
i. a first Fc polypeptide comprising substitutions at at least nine amino acid residue positions selected from the group consisting of 380, 384, 386, 387, 388, 389, 390, 413, 415, 416, and 421 according to EU numbering; and
ii. a second Fc polypeptide linked to an iduronate-2-sulfatase (IDS) enzyme, wherein the IDS amino acid sequence comprises a sequence having at least 90% identity to SEQ ID NO:1;
b. buffer, and
c. salt
wherein the pH of said pharmaceutical composition is about 5.5-7.0.
(Item 2)
The pharmaceutical composition according to item 1, wherein said buffer is selected from the group consisting of phosphate buffer, acetate buffer, arginine buffer and histidine buffer.
(Item 3)
3. The pharmaceutical composition according to item 2, wherein the phosphate buffer is sodium phosphate buffer or potassium phosphate buffer.
(Item 4)
The pharmaceutical composition according to any one of items 1-3, wherein said salt is a sodium salt.
(Item 5)
5. The pharmaceutical composition according to item 4, wherein said sodium salt is selected from the group consisting of sodium chloride, sodium sulfate and sodium phosphate.
(Item 6)
The pharmaceutical composition according to any one of items 1-5, wherein said pharmaceutical composition further comprises a surfactant.
(Item 7)
The pharmaceutical composition according to any one of items 1 to 6, wherein said pharmaceutical composition further comprises a stabilizer comprising sugar.
(Item 8)
8. The pharmaceutical composition according to any one of items 1-7, wherein said IDS amino acid sequence comprises a sequence selected from the group consisting of SEQ ID NO: 1, 2 and 3.
(Item 9)
9. Any one of items 1-8, wherein said first Fc polypeptide comprises substitutions at amino acid residues 384, 386, 387, 388, 389, 413, 415, 416 and 421, according to EU numbering. pharmaceutical composition of
(Item 10)
10. The pharmaceutical composition of any one of items 1-9, wherein said IDS amino acid sequence is linked to the N-terminus of said second Fc polypeptide.
(Item 11)
11. The pharmaceutical composition of any one of items 1-10, wherein said second Fc polypeptide linked to said IDS amino acid sequence comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 4 or 5. .
(Item 12)
11. The pharmaceutical composition of any one of items 1-10, wherein said second Fc polypeptide linked to said IDS amino acid sequence comprises the amino acid sequence of SEQ ID NO: 4 or 5.
(Item 13)
13. Pharmaceutical composition according to any one of items 1-12, wherein said first Fc polypeptide comprises a sequence having at least 90% identity with SEQ ID NO:6.
(Item 14)
13. Pharmaceutical composition according to any one of items 1-12, wherein said first Fc polypeptide comprises a sequence having at least 95% identity with SEQ ID NO:6.
(Item 15)
The first Fc polypeptide is
a. Trp, Leu, or Glu at position 380;
b. Tyr in 384th place,
c. Thr in 386th place,
d. Glu in 387th place,
e. Trp at 388th place,
f. Ser or Ala at position 389,
g. Ser or Asn at position 390,
h. Thr in 413th place,
i. Glu in 415th place,
j. Glu at position 416, and
k. Phe in 421st place
The pharmaceutical composition according to any one of items 1 to 14, comprising
(Item 16)
said second Fc polypeptide, wherein said first Fc polypeptide comprises an amino acid sequence having at least 95% sequence identity with any one of SEQ ID NOs: 6, 7, 25 and 30, linked to said IDS amino acid sequence; comprises an amino acid sequence having at least 95% sequence identity with SEQ ID NO: 4 or 5.
(Item 17)
17. The pharmaceutical composition of item 16, wherein said first Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 6 and said second Fc polypeptide linked to said IDS amino acid sequence comprises the sequence of SEQ ID NO: 4 or 5. thing.
(Item 18)
17. The pharmaceutical composition of item 16, wherein said first Fc polypeptide comprises the amino acid sequence of SEQ ID NO:7 and said second Fc polypeptide linked to said IDS amino acid sequence comprises the sequence of SEQ ID NO:4 or 5. thing.
(Item 19)
17. The pharmaceutical composition of item 16, wherein said first Fc polypeptide comprises the amino acid sequence of SEQ ID NO:25 and said second Fc polypeptide linked to said IDS amino acid sequence comprises the sequence of SEQ ID NO:4 or 5. thing.
(Item 20)
17. The pharmaceutical composition of item 16, wherein said first Fc polypeptide comprises the amino acid sequence of SEQ ID NO:30 and said second Fc polypeptide linked to said IDS amino acid sequence comprises the sequence of SEQ ID NO:4 or 5. thing.
(Item 21)
said second Fc polypeptide wherein said first Fc polypeptide comprises an amino acid sequence having at least 95% sequence identity with any one of SEQ ID NOs: 41, 42, 44 and 49, and linked to said IDS amino acid sequence comprises an amino acid sequence having at least 95% sequence identity with SEQ ID NO: 39 or 40.
(Item 22)
22. The pharmaceutical composition of item 21, wherein said first Fc polypeptide comprises the amino acid sequence of SEQ ID NO:41 and said second Fc polypeptide linked to said IDS amino acid sequence comprises the sequence of SEQ ID NO:39 or 40. thing.
(Item 23)
22. The pharmaceutical composition of item 21, wherein said first Fc polypeptide comprises the amino acid sequence of SEQ ID NO:42 and said second Fc polypeptide linked to said IDS amino acid sequence comprises the sequence of SEQ ID NO:39 or 40. thing.
(Item 24)
22. The pharmaceutical composition of item 21, wherein said first Fc polypeptide comprises the amino acid sequence of SEQ ID NO:44 and said second Fc polypeptide linked to said IDS amino acid sequence comprises the sequence of SEQ ID NO:39 or 40. thing.
(Item 25)
22. The pharmaceutical composition of item 21, wherein said first Fc polypeptide comprises the amino acid sequence of SEQ ID NO:49 and said second Fc polypeptide linked to said IDS amino acid sequence comprises the sequence of SEQ ID NO:39 or 40. thing.
(Item 26)
26. The pharmaceutical composition of any one of items 1-25, wherein the concentration of said protein molecule is about 5-50 mg/mL.
(Item 27)
27. The pharmaceutical composition of any one of items 1-26, wherein the concentration of said protein molecule is about 10-30 mg/mL.
(Item 28)
28. The pharmaceutical composition of any one of items 1-27, wherein the protein molecule has a concentration of about 10 mg/mL.
(Item 29)
28. The pharmaceutical composition of any one of items 1-27, wherein the concentration of said protein molecule is about 20 mg/mL.
(Item 30)
28. The pharmaceutical composition of any one of items 1-27, wherein the protein molecule has a concentration of about 30 mg/mL.
(Item 31)
31. The pharmaceutical composition of any one of items 1-30, wherein the concentration of said buffer is about 5-50 mM.
(Item 32)
32. The pharmaceutical composition of any one of items 1-31, wherein the concentration of said buffer is about 10-30 mM.
(Item 33)
33. The pharmaceutical composition of any one of items 1-32, wherein the concentration of said buffer is about 20 mM.
(Item 34)
34. The pharmaceutical composition of any one of items 1-33, wherein the concentration of said salt is about 30-150 mM.
(Item 35)
35. The pharmaceutical composition of any one of items 1-34, wherein the concentration of said salt is about 50-137 mM.
(Item 36)
36. Pharmaceutical composition according to any one of items 1-35, wherein the concentration of said salt is about 50 mM.
(Item 37)
36. The pharmaceutical composition of any one of items 1-35, wherein the concentration of said salt is about 137 mM.
(Item 38)
38. The pharmaceutical composition of any one of items 6-37, wherein the concentration of said surfactant is about 0.1-1.0 mg/mL.
(Item 39)
39. The pharmaceutical composition of any one of items 6-38, wherein the concentration of said surfactant is about 0.2-0.6 mg/mL.
(Item 40)
40. The pharmaceutical composition of any one of items 6-39, wherein the concentration of said surfactant is about 0.4 mg/mL.
(Item 41)
40. The pharmaceutical composition of any one of items 6-39, wherein the concentration of said surfactant is about 0.6 mg/mL.
(Item 42)
42. The pharmaceutical composition of any one of items 6-41, wherein said surfactant comprises polysorbate.
(Item 43)
43. The pharmaceutical composition according to item 42, wherein said surfactant is selected from the group consisting of polysorbate-20 (PS-20) and polysorbate-80 (PS-80).
(Item 44)
The pharmaceutical composition according to item 43, wherein said surfactant is polysorbate-20 (PS-20).
(Item 45)
The pharmaceutical composition according to item 43, wherein said surfactant is polysorbate-80 (PS-80).
(Item 46)
46. Pharmaceutical composition according to any one of items 7-45, wherein said stabilizer comprises a sugar selected from sucrose or trehalose.
(Item 47)
47. The pharmaceutical composition of any one of items 7-46, wherein the sugar concentration is about 100-250 mM.
(Item 48)
48. Pharmaceutical composition according to any one of items 7-47, wherein the sugar concentration is about 175 mM.
(Item 49)
49. Pharmaceutical composition according to any one of items 7-48, wherein said stabilizer comprises sucrose.
(Item 50)
50. Pharmaceutical composition according to any one of items 1-49, wherein said composition further comprises methionine.
(Item 51)
51. The pharmaceutical composition of item 50, wherein the concentration of methionine is about 5-20 mM.
(Item 52)
52. The pharmaceutical composition of any one of items 50 or 51, wherein the concentration of methionine is about 10 mM.
(Item 53)
53. The pharmaceutical composition of any one of items 1-52, wherein said pH of said pharmaceutical composition is about 5.5-6.5.
(Item 54)
53. The pharmaceutical composition of any one of items 1-52, wherein said pH of said pharmaceutical composition is about 6.5±0.5.
(Item 55)
55. The pharmaceutical composition of any one of items 1-54, wherein said protein molecule remains intact at a pH of about 5.5-7.0.
(Item 56)
56. Pharmaceutical composition according to any one of items 1-55, wherein said pharmaceutical composition is provided as a liquid composition.
(Item 57)
56. Pharmaceutical composition according to any one of items 1-55, wherein said pharmaceutical composition is provided as a lyophilized composition.
(Item 58)
A method of treating Hunter's Syndrome in a subject in need thereof, said method comprising providing a pharmaceutical composition according to any one of items 1-57 and administering it to said subject. Method.
(Item 59)
59. The method of item 58, wherein said pharmaceutical composition is administered intravenously.
(Item 60)
58. A pharmaceutical composition according to any one of items 1 to 57, for use in treating Hunter's Syndrome in a subject in need thereof.
(Item 61)
Use of a pharmaceutical composition as described in any one of items 1-57 in the preparation of a medicament for treating Hunter's Syndrome in a subject in need thereof.
Claims (17)
a.以下を含むタンパク質分子:
i.EU番号付けによる、380、384、386、387、388、389、390、413、415、416、及び421からなる群から選択される少なくとも9つのアミノ酸残基位置に置換を含む第1Fcポリペプチド、ならびに
ii.イズロン酸-2-スルファターゼ(IDS)酵素に連結される第2Fcポリペプチドであって、IDSアミノ酸配列が、配列番号:1と少なくとも90%の同一性を有する配列を含む前記第2Fcポリペプチド、
b.緩衝液、ならびに
c.塩
を含み、前記医薬組成物のpHが、約5.5~7.0である、前記医薬組成物。 A pharmaceutical composition comprising
a. Protein molecules containing:
i. a first Fc polypeptide comprising substitutions at at least nine amino acid residue positions selected from the group consisting of 380, 384, 386, 387, 388, 389, 390, 413, 415, 416, and 421 according to EU numbering; and ii. a second Fc polypeptide linked to an iduronate-2-sulfatase (IDS) enzyme, wherein the IDS amino acid sequence comprises a sequence having at least 90% identity to SEQ ID NO:1;
b. a buffer, and c. Said pharmaceutical composition comprising a salt, wherein said pharmaceutical composition has a pH of about 5.5 to 7.0.
(b)前記塩がナトリウム塩であり、必要に応じて、前記ナトリウム塩が、塩化ナトリウム、硫酸ナトリウム、及びリン酸ナトリウムからなる群から選択される、および/または
(c)前記医薬組成物が界面活性剤をさらに含む、および/または
(d)前記医薬組成物が、糖を含む安定剤をさらに含む、
請求項1に記載の医薬組成物。 (a) said buffer is selected from the group consisting of phosphate buffer, acetate buffer, arginine buffer and histidine buffer, and optionally said buffer is sodium phosphate buffer or phosphoric acid is a potassium buffer; and/or
(b) said salt is a sodium salt, optionally said sodium salt is selected from the group consisting of sodium chloride, sodium sulfate and sodium phosphate; and/or
(c) said pharmaceutical composition further comprises a surfactant, and/or
(d) the pharmaceutical composition further comprises a sugar-containing stabilizer;
A pharmaceutical composition according to claim 1 .
a.380位にTrp、Leu、またはGlu、
b.384位にTyr、
c.386位にThr、
d.387位にGlu、
e.388位にTrp、
f.389位にSerまたはAla、
g.390位にSerまたはAsn、
h.413位にThr、
i.415位にGlu、
j.416位にGlu、及び
k.421位にPhe
を含む、請求項1~8のいずれか1項に記載の医薬組成物。 The first Fc polypeptide is
a. Trp, Leu, or Glu at position 380;
b. Tyr in 384th place,
c. Thr in 386th place,
d. Glu in 387th place,
e. Trp at 388th place,
f. Ser or Ala at position 389,
g. Ser or Asn at position 390,
h. Thr in 413th place,
i. Glu in 415th place,
j. Glu at position 416, and k. Phe in 421st place
The pharmaceutical composition according to any one of claims 1 to 8 , comprising
2)前記第1Fcポリペプチドが、配列番号:41、42、44及び49のうちいずれか1つと少なくとも95%の配列同一性を有するアミノ酸配列を含み、前記IDSアミノ酸配列に連結される前記第2Fcポリペプチドが、配列番号:39または40と少なくとも95%の配列同一性を有するアミノ酸配列を含む、
請求項1~9のいずれか1項に記載の医薬組成物。 1) said second Fc, wherein said first Fc polypeptide comprises an amino acid sequence having at least 95% sequence identity with any one of SEQ ID NOs: 6, 7, 25 and 30, linked to said IDS amino acid sequence; the polypeptide comprises an amino acid sequence having at least 95% sequence identity with SEQ ID NO: 4 or 5, or
2) said second Fc, wherein said first Fc polypeptide comprises an amino acid sequence having at least 95% sequence identity with any one of SEQ ID NOS: 41, 42, 44 and 49, and is linked to said IDS amino acid sequence; the polypeptide comprises an amino acid sequence having at least 95% sequence identity with SEQ ID NO: 39 or 40;
The pharmaceutical composition according to any one of claims 1-9 .
b)前記第1Fcポリペプチドが、配列番号:7のアミノ酸配列を含み、前記IDSアミノ酸配列に連結される前記第2Fcポリペプチドが、配列番号:4または5の配列を含む、
c)前記第1Fcポリペプチドが、配列番号:25のアミノ酸配列を含み、前記IDSアミノ酸配列に連結される前記第2Fcポリペプチドが、配列番号:4または5の配列を含む、
d)前記第1Fcポリペプチドが、配列番号:30のアミノ酸配列を含み、前記IDSアミノ酸配列に連結される前記第2Fcポリペプチドが、配列番号:4または5の配列を含む、
e)前記第1Fcポリペプチドが、配列番号:41のアミノ酸配列を含み、前記IDSアミノ酸配列に連結される前記第2Fcポリペプチドが、配列番号:39または40の配列を含む、
f)前記第1Fcポリペプチドが、配列番号:42のアミノ酸配列を含み、前記IDSアミノ酸配列に連結される前記第2Fcポリペプチドが、配列番号:39または40の配列を含む、
g)前記第1Fcポリペプチドが、配列番号:44のアミノ酸配列を含み、前記IDSアミノ酸配列に連結される前記第2Fcポリペプチドが、配列番号:39または40の配列を含む、または
h)前記第1Fcポリペプチドが、配列番号:49のアミノ酸配列を含み、前記IDSアミノ酸配列に連結される前記第2Fcポリペプチドが、配列番号:39または40の配列を含む、
請求項10に記載の医薬組成物。 a) said first Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 6 and said second Fc polypeptide linked to said IDS amino acid sequence comprises the sequence of SEQ ID NO: 4 or 5;
b) said first Fc polypeptide comprises the amino acid sequence of SEQ ID NO:7 and said second Fc polypeptide linked to said IDS amino acid sequence comprises the sequence of SEQ ID NO:4 or 5;
c) said first Fc polypeptide comprises the amino acid sequence of SEQ ID NO:25 and said second Fc polypeptide linked to said IDS amino acid sequence comprises the sequence of SEQ ID NO:4 or 5;
d) said first Fc polypeptide comprises the amino acid sequence of SEQ ID NO:30 and said second Fc polypeptide linked to said IDS amino acid sequence comprises the sequence of SEQ ID NO:4 or 5;
e) said first Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 41 and said second Fc polypeptide linked to said IDS amino acid sequence comprises the sequence of SEQ ID NO: 39 or 40;
f) said first Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 42 and said second Fc polypeptide linked to said IDS amino acid sequence comprises the sequence of SEQ ID NO: 39 or 40;
g) said first Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 44 and said second Fc polypeptide linked to said IDS amino acid sequence comprises the sequence of SEQ ID NO: 39 or 40, or
h) said first Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 49 and said second Fc polypeptide linked to said IDS amino acid sequence comprises the sequence of SEQ ID NO: 39 or 40;
A pharmaceutical composition according to claim 10 .
(b)前記緩衝液の濃度が、約5~50mM、約10~30mM、または約20mMである、および/または
(c)前記塩の濃度が、約30~150mM、約50~137mM、約50mM、または約137mMである、
請求項1~11のいずれか1項に記載の医薬組成物。 (a) the protein molecule has a concentration of about 5-50 mg/mL , about 10-30 mg/mL, about 10 mg/mL, about 20 mg/mL, or about 30 mg/mL , and/or
(b) the concentration of said buffer is about 5-50 mM, about 10-30 mM, or about 20 mM, and/or
(c) the salt concentration is about 30-150 mM, about 50-137 mM, about 50 mM, or about 137 mM;
The pharmaceutical composition according to any one of claims 1-11 .
(b)前記界面活性剤がポリソルベートを含み、必要に応じて、前記界面活性剤が、ポリソルベート-20(PS-20)またはポリソルベート-80(PS-80)である、および/または
(c)前記安定剤が、スクロースまたはトレハロースから選択される糖を含み、必要に応じて、前記安定剤がスクロースを含む、および/または
(d)前記糖の濃度が、約100~250mM、必要に応じて、約175mMである、
請求項2~12のいずれか1項に記載の医薬組成物。 (a) the surfactant has a concentration of about 0.1-1.0 mg/mL , about 0.2-0.6 mg/mL, about 0.4 mg/mL, or about 0.6 mg/mL ; and/or
(b) said surfactant comprises polysorbate, optionally said surfactant is polysorbate-20 (PS-20) or polysorbate-80 (PS-80), and/or
(c) said stabilizer comprises a sugar selected from sucrose or trehalose, optionally said stabilizer comprises sucrose, and/or
(d) the sugar concentration is about 100-250 mM, optionally about 175 mM;
The pharmaceutical composition according to any one of claims 2-12 .
(b)前記医薬組成物の前記pHが約5.5~6.5または約6.5±0.5である、および/または
(c)前記タンパク質分子が、約5.5~7.0のpHでインタクトなままである、および/または
(d)前記医薬組成物が、液体組成物としてまたは凍結乾燥組成物として提供される、
請求項1~13のいずれか1項に記載の医薬組成物。 (a) said composition further comprises methionine, optionally wherein said methionine has a concentration of about 5-20 mM, optionally about 10 mM, and/or
(b) said pH of said pharmaceutical composition is about 5.5 to 6.5 or about 6.5±0.5, and/or
(c) said protein molecule remains intact at a pH of about 5.5 to 7.0, and/or
(d) the pharmaceutical composition is provided as a liquid composition or as a lyophilized composition;
The pharmaceutical composition according to any one of claims 1-13 .
Use of a pharmaceutical composition as defined in any one of claims 1 to 14 in the preparation of a medicament for treating Hunter's Syndrome in a subject in need thereof.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962828859P | 2019-04-03 | 2019-04-03 | |
US62/828,859 | 2019-04-03 | ||
US201962832032P | 2019-04-10 | 2019-04-10 | |
US62/832,032 | 2019-04-10 | ||
PCT/US2020/026669 WO2020206320A1 (en) | 2019-04-03 | 2020-04-03 | Formulations of protein molecules comprising iduronate 2-sulfatase |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022526799A JP2022526799A (en) | 2022-05-26 |
JPWO2020206320A5 true JPWO2020206320A5 (en) | 2023-04-03 |
Family
ID=70457135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021558657A Pending JP2022526799A (en) | 2019-04-03 | 2020-04-03 | Preparation of protein molecule containing isulonic acid 2-sulfatase |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220184186A1 (en) |
EP (1) | EP3947661A1 (en) |
JP (1) | JP2022526799A (en) |
KR (1) | KR20220004651A (en) |
CN (1) | CN113785054A (en) |
AU (1) | AU2020252554A1 (en) |
BR (1) | BR112021019520A2 (en) |
CA (1) | CA3134538A1 (en) |
MX (1) | MX2021011612A (en) |
WO (1) | WO2020206320A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE060983T2 (en) | 2017-02-17 | 2023-05-28 | Denali Therapeutics Inc | Engineered transferrin receptor binding polypeptides |
TW201925236A (en) | 2017-10-02 | 2019-07-01 | 美商戴納立製藥公司 | Fusion proteins comprising enzyme replacement therapy enzymes |
BR112020022610A2 (en) | 2018-05-10 | 2021-02-09 | Regeneron Pharmaceuticals, Inc. | high concentration vegf receptor fusion protein containing formulations |
PE20230036A1 (en) | 2019-12-23 | 2023-01-10 | Denali Therapeutics Inc | PROGRANULIN VARIANTS |
IL294655A (en) | 2020-01-13 | 2022-09-01 | Denali Therapeutics Inc | Anti-trem2 antibodies and methods of use thereof |
KR20230086703A (en) | 2020-10-14 | 2023-06-15 | 데날리 테라퓨틱스 인크. | Fusion protein containing sulfoglucosamine sulfohydrolase enzyme and method thereof |
EP4373511A1 (en) | 2021-07-23 | 2024-05-29 | Denali Therapeutics Inc. | Methods for the treatment of hunter syndrome |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2485761T (en) * | 2009-10-09 | 2019-05-30 | Armagen Inc | Methods and compositions for increasing iduronate 2-sulfatase activity in the cns |
WO2015009052A1 (en) * | 2013-07-16 | 2015-01-22 | 일동제약 주식회사 | Fusion protein of immunoglobulin hybrid fc and enzyme |
EP3556399A1 (en) * | 2016-12-19 | 2019-10-23 | Hanmi Pharm. Co., Ltd. | Brain targeting long-acting protein conjugate |
US20200230253A1 (en) * | 2017-07-28 | 2020-07-23 | HANMl PHARM. CO., LTD. | Conjugate of iduronate-2-sulfatase |
TW201925236A (en) * | 2017-10-02 | 2019-07-01 | 美商戴納立製藥公司 | Fusion proteins comprising enzyme replacement therapy enzymes |
-
2020
- 2020-04-03 BR BR112021019520A patent/BR112021019520A2/en unknown
- 2020-04-03 US US17/600,527 patent/US20220184186A1/en active Pending
- 2020-04-03 JP JP2021558657A patent/JP2022526799A/en active Pending
- 2020-04-03 EP EP20721359.6A patent/EP3947661A1/en active Pending
- 2020-04-03 MX MX2021011612A patent/MX2021011612A/en unknown
- 2020-04-03 CA CA3134538A patent/CA3134538A1/en active Pending
- 2020-04-03 WO PCT/US2020/026669 patent/WO2020206320A1/en unknown
- 2020-04-03 AU AU2020252554A patent/AU2020252554A1/en active Pending
- 2020-04-03 KR KR1020217035336A patent/KR20220004651A/en unknown
- 2020-04-03 CN CN202080033104.6A patent/CN113785054A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190071496A1 (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
JP5235661B2 (en) | Stabilized polypeptide preparation | |
JP6356106B2 (en) | Lyophilized therapeutic peptibody formulation | |
TWI548424B (en) | Stable liquid formulation of etanercept | |
JP6385345B2 (en) | Liquid formulation of long-acting insulinotropic peptide conjugate | |
TWI605824B (en) | A liquid formulation of long-acting insulin conjugate | |
WO2011012637A4 (en) | Subcutaneous anti-her2 antibody formulation | |
TW201021825A (en) | Lyophilized recombinant VWF formulations | |
NO327302B1 (en) | Storage stable composition, sealed rudder or cartridge containing said composition as well as process for their preparation | |
JP2021504372A5 (en) | ||
US20220184186A1 (en) | Formulations of protein molecules comprising iduronate 2-sulfatase | |
SK137895A3 (en) | Stable liquid compositions of gamma interferon | |
JPWO2020206320A5 (en) | ||
ES2385888T3 (en) | Stable aqueous solution of human erythropoietin that does not contain serum albumin | |
JP2024003211A (en) | Formulations for improved stability of recombinant human parathyroid hormone | |
CN114126584A (en) | Recombinant protein stabilizing formulations | |
KR20210078514A (en) | Formulations of anti-RSV antibodies and methods of use thereof | |
JPH10330284A (en) | Protector of hepatic cell | |
KR20230121823A (en) | Pharmaceutical composition of GLP-1/GLP-2 dual agonists | |
CN112494658A (en) | Stable Fc fusion protein preparation | |
EA026073B1 (en) | Formulation for bovine granulocyte colony stimulating factor and method of treatment using same | |
CA2876990C (en) | Protein to promote blood vessel growth and uses thereof | |
KR20230165799A (en) | Preparation of L-asparaginase |